Enlivex Therapeutics Ltd.
ENLV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.17 | 0.07 | 0.05 | -0.01 |
| FCF Yield | -9.27% | -4.51% | -21.92% | -16.21% |
| EV / EBITDA | -10.13 | -8.46 | -5.77 | -4.45 |
| Quality | ||||
| ROIC | -14.06% | -15.55% | -16.53% | -23.35% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.04 | 0.64 | 1.34 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -92.45% | 74.12% | -12.12% | -58.13% |
| Safety | ||||
| Net Debt / EBITDA | 1.65 | 0.47 | 0.45 | 0.54 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -416.67 | -573.88 | -533.00 | -2,027.50 |